Covetrus Inc (CVET) Insider Timothy Ludlow Sells 81,498 Shares

Covetrus Inc (NASDAQ:CVET) insider Timothy Ludlow sold 81,498 shares of the firm’s stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $28.01, for a total transaction of $2,282,758.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

NASDAQ:CVET traded down $0.07 on Tuesday, reaching $28.05. 1,005,807 shares of the stock traded hands, compared to its average volume of 1,547,242. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.82 and a quick ratio of 0.91. Covetrus Inc has a 1-year low of $27.02 and a 1-year high of $43.83.

Covetrus (NASDAQ:CVET) last released its earnings results on Wednesday, May 15th. The company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.03). The business had revenue of $941.00 million for the quarter, compared to analyst estimates of $993.41 million. The business’s revenue for the quarter was down .6% on a year-over-year basis. During the same period in the previous year, the company earned $0.18 earnings per share. As a group, equities research analysts anticipate that Covetrus Inc will post 0.68 earnings per share for the current year.

A number of research analysts recently issued reports on CVET shares. Zacks Investment Research lowered shares of Covetrus from a “hold” rating to a “sell” rating in a report on Friday, April 19th. Svb Leerink reiterated an “outperform” rating on shares of Covetrus in a report on Wednesday, March 20th. Cleveland Research assumed coverage on shares of Covetrus in a report on Friday, May 10th. They issued a “hold” rating for the company. William Blair assumed coverage on shares of Covetrus in a research report on Tuesday, February 12th. They set an “outperform” rating for the company. Finally, Credit Suisse Group assumed coverage on shares of Covetrus in a research report on Thursday, April 4th. They set a “neutral” rating and a $35.00 target price for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. Covetrus presently has a consensus rating of “Hold” and a consensus price target of $40.00.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at

Covetrus Company Profile

Covetrus, Inc engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded on April 13, 2018 and is headquartered in Melville, NY.

Recommended Story: The Role of a Fiduciary and Individual Investors

Receive News & Ratings for Covetrus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covetrus and related companies with's FREE daily email newsletter.